Alkermes (ALKS) Stock Forecast & Price Target

Alkermes PLC is positioned for revenue growth through 2030, driven by a favorable transition from Invega royalties and patent expirations while benefiting from the recent acquisition of Lumryz, which is projected to generate annualized sales of approximately $265-$275 million by 2025. The company's strategy includes investing in the development of alixorexton and capitalizing on the ongoing growth of Aristada and Lybalvi, supporting a positive outlook for its earnings per share (EPS). Additionally, the encouraging efficacy data for alixorexton and the strategic addition of Lumryz as a commercial asset are expected to enhance both immediate revenues and the company's future growth potential.

Alkermes PLC faces a negative outlook primarily due to projected modest sales growth for its product Lumryz, which is expected to peak at approximately $600 million by 2030 before experiencing declines post-loss of exclusivity in 2037. The company is also at risk of significant downside if its orexin program fails, compounded by emerging competition in the narcolepsy market from other orexin receptor agonists, leading to concerns over a stagnant growth trajectory for the Lumryz franchise. Key risks include erosion of its royalty business, early-stage efficacy uncertainty of the orexin data, and substantial exposure to Medicaid, all of which could pressure earnings through the remainder of the decade.